Player FM - Internet Radio Done Right
191 subscribers
Checked 8h ago
Добавлено три года назад
Контент предоставлен ReachMD. Весь контент подкастов, включая эпизоды, графику и описания подкастов, загружается и предоставляется непосредственно компанией ReachMD или ее партнером по платформе подкастов. Если вы считаете, что кто-то использует вашу работу, защищенную авторским правом, без вашего разрешения, вы можете выполнить процедуру, описанную здесь https://ru.player.fm/legal.
Player FM - приложение для подкастов
Работайте офлайн с приложением Player FM !
Работайте офлайн с приложением Player FM !
Подкасты, которые стоит послушать
РЕКЛАМА
<
<div class="span index">1</div> <span><a class="" data-remote="true" data-type="html" href="/series/all-about-change">All About Change</a></span>


How do we build an inclusive world? Hear intimate and in-depth conversations with changemakers on disability rights, youth mental health advocacy, prison reform, grassroots activism, and more. First-hand stories about activism, change, and courage from people who are changing the world: from how a teen mom became the Planned Parenthood CEO, to NBA player Kevin Love on mental health in professional sports, to Beetlejuice actress Geena Davis on Hollywood’s role in women’s rights. All About Change is hosted by Jay Ruderman, whose life’s work is seeking social justice and inclusion for people with disabilities worldwide. Join Jay as he interviews iconic guests who have gone through adversity and harnessed their experiences to better the world. This show ultimately offers the message of hope that we need to keep going. All About Change is a production of the Ruderman Family Foundation. Listen and subscribe to All About Change wherever you get podcasts. https://allaboutchangepodcast.com/
Insights to Pharmaceutical Approaches in COPD
Manage episode 456217371 series 3128163
Контент предоставлен ReachMD. Весь контент подкастов, включая эпизоды, графику и описания подкастов, загружается и предоставляется непосредственно компанией ReachMD или ее партнером по платформе подкастов. Если вы считаете, что кто-то использует вашу работу, защищенную авторским правом, без вашего разрешения, вы можете выполнить процедуру, описанную здесь https://ru.player.fm/legal.
CME credits: 0.50
Valid until: 18-10-2025
Claim your CME credit at https://reachmd.com/programs/cme/insights-to-pharmaceutical-approaches-in-copd/27036/
Although chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide, current management does not alter progression of the disease. With the potential for biologically-targeted therapies to be available soon, it is important to address current educational needs related to COPD. This includes knowledge of T2 inflammation in COPD, understanding the clinician’s role in assessing patients for inflammatory types, staying in formed about developing therapies, and adopting strategies that shift COPD management to a more personalized approach.
…
continue reading
Valid until: 18-10-2025
Claim your CME credit at https://reachmd.com/programs/cme/insights-to-pharmaceutical-approaches-in-copd/27036/
Although chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide, current management does not alter progression of the disease. With the potential for biologically-targeted therapies to be available soon, it is important to address current educational needs related to COPD. This includes knowledge of T2 inflammation in COPD, understanding the clinician’s role in assessing patients for inflammatory types, staying in formed about developing therapies, and adopting strategies that shift COPD management to a more personalized approach.
462 эпизодов
Manage episode 456217371 series 3128163
Контент предоставлен ReachMD. Весь контент подкастов, включая эпизоды, графику и описания подкастов, загружается и предоставляется непосредственно компанией ReachMD или ее партнером по платформе подкастов. Если вы считаете, что кто-то использует вашу работу, защищенную авторским правом, без вашего разрешения, вы можете выполнить процедуру, описанную здесь https://ru.player.fm/legal.
CME credits: 0.50
Valid until: 18-10-2025
Claim your CME credit at https://reachmd.com/programs/cme/insights-to-pharmaceutical-approaches-in-copd/27036/
Although chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide, current management does not alter progression of the disease. With the potential for biologically-targeted therapies to be available soon, it is important to address current educational needs related to COPD. This includes knowledge of T2 inflammation in COPD, understanding the clinician’s role in assessing patients for inflammatory types, staying in formed about developing therapies, and adopting strategies that shift COPD management to a more personalized approach.
…
continue reading
Valid until: 18-10-2025
Claim your CME credit at https://reachmd.com/programs/cme/insights-to-pharmaceutical-approaches-in-copd/27036/
Although chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide, current management does not alter progression of the disease. With the potential for biologically-targeted therapies to be available soon, it is important to address current educational needs related to COPD. This includes knowledge of T2 inflammation in COPD, understanding the clinician’s role in assessing patients for inflammatory types, staying in formed about developing therapies, and adopting strategies that shift COPD management to a more personalized approach.
462 эпизодов
Все серии
×CME credits: 0.25 Valid until: 31-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/no-patient-left-behind-advancing-ckd-associated-pruritus-care/26637/ Patients with chronic kidney disease-associated pruritus (CKD-aP) often face delays in diagnosis and treatment, as well as potential side effects from some prescribed medicines. Tune in as our experts dive into the burden of CKD-aP symptoms and break down the long-term outcomes and benefits of new and emerging treatments.…

1 Evaluation and Management of AKI in Cirrhosis: At the Interface of Gastroenterology and Nephrology
CME credits: 0.25 Valid until: 17-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/evaluation-and-management-of-aki-in-cirrhosis-at-the-interface-of-gastroenterology-and-nephrology/26988/ In patients with advanced liver disease, decompensated cirrhosis and portal hypertension can impact kidney function through development of acute kidney injury (AKI). Multiple different etiologies of AKI can be seen in cirrhotic patients, including prerenal AKI, acute tubular injury, and hepatorenal syndrome (HRS), which require different treatment approaches. This podcast will emphasize the importance of multidisciplinary care and use of established protocols in treating these patients, particularly when considering a bridge to liver transplantation, and discuss specific considerations for patients with transjugular intrahepatic portosystemic shunt (TIPS).…
CME credits: 1.00 Valid until: 17-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/precision-medicine-in-myasthenia-gravis-crafting-personalized-treatment-strategies/32244/ The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.…
CME credits: 1.00 Valid until: 17-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/optimizing-fcrn-therapy-addressing-and-reducing-adverse-reactions/32243/ The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.…
CME credits: 1.00 Valid until: 17-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/fcrn-antagonists-in-myasthenia-gravis-a-new-era-in-targeted-therapy/32242/ The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.…
CME credits: 1.00 Valid until: 17-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/the-science-behind-fcrn-antagonists-a-deep-dive-into-their-mechanism-of-action/32241/ The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.…
CME credits: 1.00 Valid until: 17-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/balancing-risk-and-benefit-traditional-mg-treatments-and-medications-to-avoid/32240/ The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.…
CME credits: 1.00 Valid until: 17-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/autoantibodies-in-mg-their-role-in-diagnosis-and-treatment/32239/ The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.…
CME credits: 1.00 Valid until: 17-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/diagnosing-gmg-navigating-current-tools-and-approaches/32238/ The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.…
CME credits: 1.00 Valid until: 17-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/life-threatening-events-understanding-and-preventing-myasthenic-crisis/32237/ The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.…
CME credits: 1.00 Valid until: 17-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/understanding-disease-progression-the-shift-from-ocular-to-generalized-mg/32236/ The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.…
CME credits: 1.00 Valid until: 17-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/beyond-the-symptoms-the-true-impact-of-gmg-on-patients-lives/32235/ The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.…
CME credits: 0.75 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/unique-new-strategies-for-the-pharmacologic-treatment-of-dry-eye-disease-focus/29732/ Increased understanding of the neurobiology of dry eye disease (DED) has led to a greater emphasis on its significant and potentially serious impact on patients’ vision and quality of life. Emerging treatments for DED go beyond mere symptom management to target its neurobiology. Join an expert panel consisting of an ophthalmologist and an optometrist to discuss the burden and causes of DED, the role of the lacrimal functional unit in its pathophysiology, and the rationale for targeted neuromodulation. The panel will also explore the symptoms of DED and the new pharmacologic agents that target the LFU along with clinical evidence supporting their use. The program will also include a video vignette of a patient with DED to highlight the challenges and realities of living with DED.…

1 Maximizing Myeloma Outcomes With GPRC5D-Directed Therapy: Practical Expert Case Studies and Best Practices
CME credits: 0.25 Valid until: 15-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/maximizing-myeloma-outcomes-with-gprc5d-directed-therapy-practical-expert-case-studies-and-best-practices/29812/ This 15-minute audio podcast uses real-world patient cases to illustrate effective strategies for managing adverse events (AEs) associated with GPRC5D-directed therapies in multiple myeloma. Expert faculty discuss how to safely implement these therapies to achieve deep, durable responses while optimizing patient tolerability and quality of life. Listeners will gain insights into specific prophylaxis, dosing, and interprofessional management protocols to address unique AEs such as cytokine release syndrome, skin toxicity, and dysgeusia. This practical case-based discussion will equip healthcare professionals with actionable tools to improve outcomes for their patients with relapsed/refractory multiple myeloma.…
CME credits: 0.25 Valid until: 15-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/breaking-the-cycle-addressing-hyperkalemia-in-ckd-and-heart-failure-to-optimize-raasi-therapy/26746/ Patients with CKD or heart failure face the risk of developing hyperkalemia, and healthcare providers often experience clinical inertia in their treatment. Join the experts as they explore chronic hyperkalemia management, and the role of potassium binders.…
Добро пожаловать в Player FM!
Player FM сканирует Интернет в поисках высококачественных подкастов, чтобы вы могли наслаждаться ими прямо сейчас. Это лучшее приложение для подкастов, которое работает на Android, iPhone и веб-странице. Зарегистрируйтесь, чтобы синхронизировать подписки на разных устройствах.